Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (DE:IDP)
XETRA:IDP
Biogen (IDP) Stock Price & Analysis
3 Followers
IDP Stock Chart & Stats
Day’s Range€179.25 - €180.65
52-Week Range― - ―
Previous Close€182.35
Volume573.00
Average Volume (3M)N/A
Market Cap
$26.08B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Apr 24, 2024EPS Estimate
€3.23Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€268.75Price Target Upside49.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Biogen News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market ImpactLeqembi, as a potential first-to-market Alzheimer's treatment, could significantly enhance the company's market share.
Financial GrowthEarnings are anticipated to grow, with management expecting significant cost savings to materialize by 2025.
Product And Cost EfficiencyThe combination of product ramp and the company's cost cutting program is expected to improve financial performance.
Bears Say
Competitive PressuresErosion for Tysabri is expected to accelerate throughout the year due to biosimilar competition entering the market.
Financial PerformanceRevenue of $2.39bn missed analyst estimates of $2.48bn and adjusted EPS of $2.95 missed consensus of $3.18, leading to lowered expectations for the stock.
Regulatory ChallengesThe BLA filing for the SQ formulation of Leqembi is delayed due to the FDA's request for a Fast Track designation specific to the SQ formulation, causing a delay in submission.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.95% Insiders
36.29% Mutual Funds
27.99% Other Institutional Investors
33.78% Public Companies and
Individual Investors
IDP FAQ
What was Biogen’s price range in the past 12 months?
Currently, no data Available
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Apr 24, 2024 which is in 5 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Feb 13, 2024. The company reported €2.779 earnings per share for the quarter, missing the consensus estimate of €2.999 by -€0.22.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of €20.93 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is €3.23.
How many shares outstanding does Biogen have?
Currently, no data Available
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of €2.779 in its last earnings report, missing expectations of €2.999. Following the earnings report the stock price went down -3.546%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 4B.
---
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€268.75 (49.93% Upside)
€268.75 (49.93% Upside)
Blogger Sentiment
Bullish
DE:IDP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $43.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.23%
12-Months-Change
Fundamentals
Return on Equity
8.24%
Trailing 12-Months
Asset Growth
9.33%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
IDP Company Deck
---
IDP Earnings Call
Q4 2024
0:00 / 0:00
---
IDP Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
IDP Stock 12 Months Forecast
Average Price Target
€268.75
▲(49.93% Upside)
Technical Analysis
Best Analysts Covering IDP
1 Year
1 Year Success Rate
14/40 ratings generated profit
1 Year Average Return
-7.27%
assigned a buy rating 24 days ago
Copying Robyn Karnauskas's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -7.27% per trade.
---